Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27189269 | 1.00 | CTSS (0.47) | CTSSCTSKS1PR3SLC6A3KLK5 | |
| SCHEMBL2582580 | 0.87 | CTSS (0.48) | CTSSCTSKS1PR3KLK5TRPA1 | |
| SCHEMBL14254331 | 0.87 | CTSS (0.48) | CTSSCTSKS1PR3KLK5TRPA1 | |
| SCHEMBL1554126 | 0.87 | CTSS (0.48) | CTSSCTSKS1PR3KLK5TRPA1 | |
| SCHEMBL1554122 | 0.87 | CTSS (0.48) | CTSSCTSKS1PR3KLK5TRPA1 | |
| SCHEMBL3503830 | 0.85 | CTSS (0.47) | CTSSCTSKS1PR3MAPT | |
| SCHEMBL1525552 | 0.85 | S1PR3 (0.52) | CTSSCTSKS1PR3TRPA1MAPT | |
| SCHEMBL2426585 | 0.85 | NPSR1 (0.50) | CTSSCTSKS1PR3MAPTACACB | |
| SCHEMBL17723343 | 0.85 | CTSS (0.47) | CTSSCTSKS1PR3KLK5MAPT | |
| SCHEMBL13808330 | 0.85 | NPSR1 (0.50) | CTSSCTSKS1PR3MAPTACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2023-10-19 | — | — | US | disclosed |
| US-11666555-B2 | RelA inhibitors for biofilm disruption | DREXEL UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666555-B2 | RelA inhibitors for biofilm disruption | DREXEL UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-20200069647-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666555-B2 | RelA inhibitors for biofilm disruption | RELA, NFKBIA, NFKB1 | CTSS 1269/4885CTSK 1207/4885S1PR3 4639/4885 |
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | RELA, NFKBIA, NFKB1 | CTSS 1269/4885CTSK 1207/4885S1PR3 4639/4885 |
| US-20200069647-A1 | RelA Inhibitors for Biofilm Disruption | RELA, NFKBIA, NFKB1 | CTSS 1269/4885CTSK 1207/4885S1PR3 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.